J&J Is Proactive On Procrit Positioning Ahead Of Medicare Part B Changes

Johnson & Johnson is taking steps to competitively position Procrit ahead of the changes to Medicare Part B reimbursement in 2005, Biopharmaceuticals Group Chairman Joe Scodari told investors July 13